

Notes from the Pharmaceuticals Advisory Group Meeting

Weds 25 May 2016, Nantes, France

The meeting began at 5 pm. Jason Snape acted as chair. About 35 people in attendance. Introductions were made around the room.

Impressions of sessions today?

Need to make sure to include what's going on in developing countries with developing health care systems. How can ecopharmaco stewardship work in developing countries?

Treatment solutions. Effect-based monitoring. Mixtures. Risk management solutions to address microbial resistance may not tackle the issue if just look at the antibiotic alone.

Some would prefer a larger block of session time on pharmaceutical sessions. And to have pharmaceutical sessions really be about that topic. Organizing committees need to be taking consideration of session proposals. However it is not always possible because the right abstracts have to come in.

It is new for the industry to be working together. Recognize that transparency is needed. More sharing of data.

Future SETAC events

World Congress Orlando, Nov. 2016: there is a session on pharmaceutical mixtures (Jim Lazorchak).

Workshop in conjunction with Asia-Pacific meeting. On antibiotics, monitoring, citizen science. Funded by US State Department but has SETAC sponsorship. More focus on exposure versus effects. Output may be a policy recommendation paper.

SETAC Europe 2017, Brussels: Should we have a pre-meeting event? Several issues were identified through the Horizon Scanning workshop. Should discuss with Steering committee. A follow up on the 20 questions workshop? (What research is being done of the recommendations we made). Technical topic: PBT assessment for drugs. Regulatory topic: Developments in EMEA (we will be in Brussels after all). Take a different angle – invite health professionals, how do we identify and manage the top 20 hot spots that are of concern? Risk management strategies that are not end-of-pipe treatment. Mixture risk of similarly-acting API. Start to drum up awareness of issues in developing areas, e.g. Africa. Ties in with SAICM Initiative on Environmentally Persistent Pharmaceuticals.

Other topics:

EMA consultation paper on ERA, open for comments. Has 8 themes. This could serve as the basis for a session.

BIO-S report with PiE. Looks at whole life cycle. Has 84 recommendations. Consultation over the summer. Can share through PAG link.

Do we need any workshops? Pellston on human pharma assessment. Could be looked at in terms of experience so far. Addressing global issues? Vet meds? (feeding the world). Issues are different for vet meds and human meds, should keep separate. Combining with biocides? Data gap with companion animals - do we know storm sewer route? What topics would be covered in a human meds workshop - How to improve science (exposure and risk assessment) – global context – more people having access to medicines. How to produce a chicken with less drugs (Wal Mart as a driver). Antimicrobial resistance. What are the trends for new drug targets in the next decade?

Meeting closed at 6 pm. Send any questions to Mike Williams.

Respectfully submitted,

Jane Staveley